ID

22344

Descrição

A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in Treatment Phase. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Link

https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Palavras-chave

Versões (2)
  1. 30/05/2017 30/05/2017 -
  2. 30/05/2017 30/05/2017 -
Transferido a

30 de maio de 2017

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Serious Adverse Event Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

Inglês

Serious Adverse Event Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

1 Formulários  
Serious Adverse Events (SAE)
Descrição

Serious Adverse Events (SAE)

Alias
UMLS CUI-1
C1519255
Person Reporting SAE
Descrição

Name

Tipo de dados

text

Alias
UMLS CUI [1]
C0008961
Serious Adverse Event (Please print clearly) GSK Use
Descrição

Diagnosis

Tipo de dados

text

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0011900
Specify reason(s) for considering this a serious AE. Mark all that apply.
Descrição

Reason

Tipo de dados

integer

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C1519255
Specify other reason
Descrição

Specify other reason

Tipo de dados

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C1519255
Onset Date/Time
Descrição

Onset Date/Time

Tipo de dados

datetime

Alias
UMLS CUI [1]
C2985916
End Date/Time (if ongoing, please leave blank)
Descrição

End Date/Time

Tipo de dados

datetime

Alias
UMLS CUI [1]
C3899266
Outcome *If subject died, please inform GSK within 24 hours and complete Form D.
Descrição

Outcome

Tipo de dados

integer

Alias
UMLS CUI [1]
C1705586
Event Course
Descrição

Course

Tipo de dados

integer

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0750729
Intensity (maximum)
Descrição

Intensity

Tipo de dados

integer

Alias
UMLS CUI [1,1]
C0522510
UMLS CUI [1,2]
C0877248
Action taken with Respect to Investigational Drug
Descrição

Action taken

Tipo de dados

integer

Alias
UMLS CUI [1,1]
C0441472
UMLS CUI [1,2]
C0013230
Relationship to Investigational Drug
Descrição

Relationship to Investigational Drug

Tipo de dados

integer

Alias
UMLS CUI [1]
C0013230
Corrective Therapy If ´Yes`, Please record on Concomitant Medication form.
Descrição

Corrective Therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0087111
Was subject withdrawn due to this AE?
Descrição

Withdrawal

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C0877248
Serious Adverse Event
Descrição

Serious Adverse Event

Alias
UMLS CUI-1
C1519255
Did the SAE abate?
Descrição

SAE Abation

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C3853704
If study medication was interrupted, stopped or dose reduced: Was study medication reintroduced (or dose increased)?
Descrição

Trial medication

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013227
If yes, did SAE recur?
Descrição

SAE

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1519255
Assessment
Descrição

Assessment

Alias
UMLS CUI-1
C1519255
UMLS CUI-2
C1516048
The SAE is probably associated with:
Descrição

sae

Tipo de dados

integer

Alias
UMLS CUI [1]
C1706737
Please specify
Descrição

Specify SAE

Tipo de dados

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C1519255
Voltar ao início da página

Similar models

Serious Adverse Event Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Serious Adverse Events (SAE)
C1519255 (UMLS CUI-1)
Name
Item
Person Reporting SAE
text
C0008961 (UMLS CUI [1])
Diagnosis
Item
Serious Adverse Event (Please print clearly) GSK Use
text
C1519255 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
Item
Specify reason(s) for considering this a serious AE. Mark all that apply.
integer
C0392360 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Reason
Code List
Specify reason(s) for considering this a serious AE. Mark all that apply.
CL Item
results in Death (1)
CL Item
life threatening (2)
CL Item
requires hospitalization or prolongation of existing hospitalization (3)
CL Item
results in disability/incapacity (4)
CL Item
congenital anomaly/birth defect (5)
CL Item
other (see definition) (6)
Specify other reason
Item
Specify other reason
text
C0392360 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Onset Date/Time
Item
Onset Date/Time
datetime
C2985916 (UMLS CUI [1])
End Date/Time
Item
End Date/Time (if ongoing, please leave blank)
datetime
C3899266 (UMLS CUI [1])
Item
Outcome *If subject died, please inform GSK within 24 hours and complete Form D.
integer
C1705586 (UMLS CUI [1])
Outcome
Code List
Outcome *If subject died, please inform GSK within 24 hours and complete Form D.
CL Item
Resolved (1)
CL Item
Ongoing (2)
CL Item
Died (3)
Item
Event Course
integer
C0877248 (UMLS CUI [1,1])
C0750729 (UMLS CUI [1,2])
Course
Code List
Event Course
CL Item
Intermittent  (1)
CL Item
Constant (2)
Item
Intensity (maximum)
integer
C0522510 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
Intensity
Code List
Intensity (maximum)
CL Item
Mild (1)
CL Item
Moderate (3)
CL Item
Severe (3)
Item
Action taken with Respect to Investigational Drug
integer
C0441472 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Action taken
Code List
Action taken with Respect to Investigational Drug
CL Item
None (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Drug interrupted/restarted (4)
CL Item
Drug stopped (5)
Item
Relationship to Investigational Drug
integer
C0013230 (UMLS CUI [1])
trial procedures
Code List
Relationship to Investigational Drug
CL Item
Not related (1)
CL Item
Unlikely (2)
CL Item
Suspected (reasonable possibility) (3)
CL Item
Probable (4)
Corrective Therapy
Item
Corrective Therapy If ´Yes`, Please record on Concomitant Medication form.
boolean
C0087111 (UMLS CUI [1])
Withdrawal
Item
Was subject withdrawn due to this AE?
boolean
C2349954 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
Item Group
Serious Adverse Event
C1519255 (UMLS CUI-1)
SAE Abation
Item
Did the SAE abate?
boolean
C1519255 (UMLS CUI [1,1])
C3853704 (UMLS CUI [1,2])
Trial medication
Item
If study medication was interrupted, stopped or dose reduced: Was study medication reintroduced (or dose increased)?
boolean
C0013227 (UMLS CUI [1])
SAE
Item
If yes, did SAE recur?
boolean
C1519255 (UMLS CUI [1])
Item Group
Assessment
C1519255 (UMLS CUI-1)
C1516048 (UMLS CUI-2)
Item
The SAE is probably associated with:
integer
C1706737 (UMLS CUI [1])
sae
Code List
The SAE is probably associated with:
CL Item
Protocol design or procedures (but not to study drug) (1)
CL Item
Another condition (eg, condition under study, intercurrent illness) (2)
CL Item
Another drug (3)
Specify SAE
Item
Please specify
text
C0392360 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial